Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel coated balloon - Lutonix/C.R. Bard

Next Previous
Drug Profile

Paclitaxel coated balloon - Lutonix/C.R. Bard

Alternative Names: Lutonix; Lutonix 35 drug coated balloon PTA catheter; Lutonix paclitaxel DCB; Lutonix paclitaxel-coated balloon - Lutonix/CR Bard; Lutonix paclitaxel-coated PTA dilatation catheter; Lutonix® Drug Coated PTA Dilatation Catheter; MD02-LDCB; Paclitaxel-coated percutaneous transluminal angioplasty balloon - Lutonix/CR Bard

Latest Information Update: 15 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lutonix
  • Developer CR Bard; Lutonix
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Mitosis inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial disorders

Most Recent Events

  • 01 Mar 2019 CR Bard completes a phase III trial for Peripheral arterial disorders in USA (NCT02063672)
  • 25 Jun 2015 Updated efficacy results from the Levant 2 phase II trial in Peripheral arterial disorders released by C.R. Bard
  • 23 Oct 2014 Launched for Peripheral arterial disorders in USA (Intra-arterial)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top